http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2738654-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_662b83ab0cfe4fb5e89862da85be7132 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-427 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427 |
| filingDate | 2018-01-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae748602b77505279290ba59f525a195 |
| publicationDate | 2020-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2738654-C1 |
| titleOfInvention | Novel cyclin-dependent kinase cdk9 inhibitor |
| abstract | FIELD: chemistry; pharmaceutics. n SUBSTANCE: invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, where Y is selected from a group consisting of p-fluorobenzoyl, trans-4-aminocyclohexyl, in which N is optionally substituted with R 3 , and trans-4-aminocyclohexylmethyl; Z is selected from a group consisting of NH, S and O; R 1 is selected from a group consisting of hydrogen and halogen; R 2 is selected from a group consisting of hydrogen, C3-C6 cycloalkyl, 4-tetrahydropyranyl, optionally substituted with R 4 , and phenyl, optionally substituted with R 4 ; R 3 is selected from a group consisting of C2-C6 alkanoyl and C1-C3 alkoxy (C1-C3) alkyl; R 4 is selected from a group consisting of cyano and halogen. Invention also relates to a pharmaceutical composition for inhibiting cyclin-dependent kinase CDK9 based on said compound. n n n n EFFECT: technical result is obtaining novel compounds and a pharmaceutical composition based thereon, which can be used in medicine for treating cancer diseases. n 14 cl, 5 tbl, 14 dwg, 24 ex |
| priorityDate | 2017-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 388.